ONDANSETRON ACCORD ondansetron 8mg/4mL (as hydrochloride dihydrate) injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

ondansetron accord ondansetron 8mg/4ml (as hydrochloride dihydrate) injection ampoule

accord healthcare pty ltd - ondansetron hydrochloride dihydrate, quantity: 9.98 mg (equivalent: ondansetron, qty 8 mg) - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide; sodium chloride; sodium citrate dihydrate; citric acid monohydrate - ondansetron injection is indicated ? for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ? for the prevention and treatment of post-operative nausea and vomiting.

ONDANSETRON ACCORD ondansetron 4mg/2mL (as hydrochloride dihydrate) injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

ondansetron accord ondansetron 4mg/2ml (as hydrochloride dihydrate) injection ampoule

accord healthcare pty ltd - ondansetron hydrochloride dihydrate, quantity: 4.99 mg (equivalent: ondansetron, qty 4 mg) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; citric acid monohydrate; sodium citrate dihydrate; hydrochloric acid; sodium chloride - ondansetron injection is indicated ? for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ? for the prevention and treatment of post-operative nausea and vomiting.

ONDANSETRON SZ ondansetron (as hydrochloride dihydrate) 8 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

ondansetron sz ondansetron (as hydrochloride dihydrate) 8 mg film-coated tablet blister pack

dr reddys laboratories australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 10 mg (equivalent: ondansetron, qty 8 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; lactose monohydrate; pregelatinised maize starch; sodium starch glycollate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.

ONDANSETRON SZ ondansetron (as hydrochloride dihydrate) 4 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

ondansetron sz ondansetron (as hydrochloride dihydrate) 4 mg film-coated tablet blister pack

dr reddys laboratories australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 5 mg (equivalent: ondansetron, qty 4 mg) - tablet, film coated - excipient ingredients: pregelatinised maize starch; microcrystalline cellulose; sodium starch glycollate; lactose monohydrate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.

ONDANSETRON-DRLA ondansetron (as hydrochloride dihydrate) 8 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

ondansetron-drla ondansetron (as hydrochloride dihydrate) 8 mg film-coated tablet blister pack

dr reddys laboratories australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 10 mg (equivalent: ondansetron, qty 8 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.

ONDANSETRON-DRLA ondansetron (as hydrochloride dihydrate) 4 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

ondansetron-drla ondansetron (as hydrochloride dihydrate) 4 mg film-coated tablet blister pack

dr reddys laboratories australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 5 mg (equivalent: ondansetron, qty 4 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; pregelatinised maize starch; sodium starch glycollate; colloidal anhydrous silica; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.

ONDANSETRON-Baxter ondansetron (as hydrochloride) 4 mg/2 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

ondansetron-baxter ondansetron (as hydrochloride) 4 mg/2 ml solution for injection ampoule

baxter healthcare pty ltd - ondansetron hydrochloride dihydrate, quantity: 4.98 mg (equivalent: ondansetron, qty 4 mg) - injection, solution - excipient ingredients: sodium citrate dihydrate; sodium chloride; citric acid monohydrate; water for injections - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. prevention and treatment of post-operative nausea and vomiting.

APO-METOCLOPRAMIDE metoclopramide hydrochloride monohydrate 10 mg film coated tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-metoclopramide metoclopramide hydrochloride monohydrate 10 mg film coated tablets blister pack

arrotex pharmaceuticals pty ltd - metoclopramide hydrochloride monohydrate, quantity: 10 mg - tablet, film coated - excipient ingredients: maize starch; macrogol 6000; colloidal anhydrous silica; microcrystalline cellulose; purified talc; stearic acid; pregelatinised maize starch; hypromellose; titanium dioxide - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation

APX-ONDANSETRON ondansetron (as hydrochloride dihydrate) 4 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apx-ondansetron ondansetron (as hydrochloride dihydrate) 4 mg tablet blister pack

arrotex pharmaceuticals pty ltd - ondansetron hydrochloride dihydrate, quantity: 4.986 mg - tablet, film coated - excipient ingredients: magnesium stearate; pregelatinised maize starch; lactose; titanium dioxide; hypromellose; microcrystalline cellulose; triacetin - ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.

APX-ONDANSETRON ondansetron (as hydrochloride dihydrate) 8 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apx-ondansetron ondansetron (as hydrochloride dihydrate) 8 mg tablet blister pack

arrotex pharmaceuticals pty ltd - ondansetron hydrochloride dihydrate, quantity: 9.972 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; pregelatinised maize starch; lactose; titanium dioxide; hypromellose; triacetin; iron oxide yellow - ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.